| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research Communication |
1 From the Department of Nutrition, School of Public Health and School of Medicine, University of North Carolina, Chapel Hill (WM, CNC, LF, WL, CM, JP, and SHZ); the Research Triangle Institute, Research Triangle Park, NC (RAJ and MAK); and the Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD (JC).
Background: Genistein may be useful in the prevention or treatment of prostate cancer; however, it causes genetic damage in cultured human cells.
Objective: The objective was to assess the potential genotoxicity of a purified soy unconjugated isoflavone mixture in men with prostate cancer.
Design: Twenty patients with prostate cancer were treated with 300 mg genistein/d for 28 d and then with 600 mg/d for another 56 d. In peripheral lymphocytes, DNA strand breaks were assessed as nuclear tail moment, chromosomal damage was assessed as micronucleus frequency (MF), and translocations of the MLL gene (11q23) were assessed by using fluorescence in situ hybridization. Values are also reported for 6 healthy men. The studies were performed under Investigational New Drug application no. 54 137 at a tertiary referral academic medical center.
Results: No changes in group average or individual nuclear tail moment and MF were observed. We observed a single elevated MF value in one subject that exceeded a clinical threshold set before we initiated the study. A significant decrease in average COMET tail moment was observed on day 28 relative to day 0. We detected no genistein-induced rearrangements of the MLL gene in the 3 subjects we studied with this technique. MF increased significantly in lymphocytes exposed in vitro to unconjugated genistein at concentrations 
100 µmol/L. Total genistein never exceeded a peak concentration of 27.1 µmol/L, and unconjugated genistein never exceeded a peak concentration of 0.32 µmol/L.
Conclusion: Although isoflavones are capable of inducing genetic damage in vitro, a similar effect was not observed in subjects treated with a purified soy unconjugated isoflavone mixture.
Key Words: Genistein • daidzein • glycitein • soy isoflavones • lymphocytes • genotoxicity • prostate cancer
This article has been cited by other articles:
|
|
 |
|
  G. R. Wasson, V. J. McKelvey-Martin, and C. S. Downes The use of the comet assay in the study of human nutrition and cancer Mutagenesis, May 1, 2008; 23(3): 153 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Moiseeva, G. M. Almeida, G. D.D. Jones, and M. M. Manson Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 3071 - 3079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. El Touny and P. P. Banerjee Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype Carcinogenesis, August 1, 2007; 28(8): 1710 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rice, R. Handayani, Y. Cui, T. Medrano, V. Samedi, H. Baker, N. J. Szabo, C. J. Rosser, S. Goodison, and K. T. Shiverick Soy Isoflavones Exert Differential Effects on Androgen Responsive Genes in LNCaP Human Prostate Cancer Cells J. Nutr., April 1, 2007; 137(4): 964 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Steiner, W. H.M. Peters, E. P. Gallagher, P. Magee, I. Rowland, and B. L. Pool-Zobel Genistein protects human mammary epithelial cells from benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide and 4-hydroxy-2-nonenal genotoxicity by modulating the glutathione/glutathione S-transferase system Carcinogenesis, March 1, 2007; 28(3): 738 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Raschke, I. R. Rowland, P. J. Magee, and B. L. Pool-Zobel Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress Carcinogenesis, November 1, 2006; 27(11): 2322 - 2330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Mezei, Y. Li, E. Mullen, J. S. Ross-Viola, and N. F. Shay Dietary isoflavone supplementation modulates lipid metabolism via PPAR{alpha}-dependent and -independent mechanisms Physiol Genomics, September 14, 2006; 26(1): 8 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Handayani, L. Rice, Y. Cui, T. A. Medrano, V. G. Samedi, H. V. Baker, N. J. Szabo, and K. T. Shiverick Soy Isoflavones Alter Expression of Genes Associated with Cancer Progression, Including Interleukin-8, in Androgen-Independent PC-3 Human Prostate Cancer Cells J. Nutr., January 1, 2006; 136(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Aguero, M. M. Facchinetti, Z. Sheleg, and A. M. Senderowicz Phenoxodiol, a Novel Isoflavone, Induces G1 Arrest by Specific Loss in Cyclin-Dependent Kinase 2 Activity by p53-Independent Induction of p21WAF1/CIP1 Cancer Res., April 15, 2005; 65(8): 3364 - 3373. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
